Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Affluent Partners Holdings ( (HK:1466) ) has shared an update.
Baijin Life Science Holdings has appointed Ms. Shen Ding as an independent non‑executive director and member of its audit, remuneration and nomination committees, effective 2 March 2026. Shen brings experience in equity investment, asset management and securities regulation, having previously held senior roles at Mingya Fund Management, Beijing Xiangyi Asset Management and the China Securities Regulatory Commission.
With Shen’s appointment, the board now includes three independent non‑executive directors, enabling Baijin Life Science to restore full compliance with Hong Kong listing rules governing board independence and key governance committees. Her addition is expected to strengthen the company’s corporate governance framework and reassure investors about its adherence to regulatory standards and oversight requirements.
The most recent analyst rating on (HK:1466) stock is a Sell with a HK$0.49 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.
More about Affluent Partners Holdings
Baijin Life Science Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the life sciences sector. The company is governed by a board comprising executive, non‑executive and independent non‑executive directors, reflecting a typical Hong Kong–listed corporate structure focused on regulatory compliance and oversight.
YTD Price Performance: 5.88%
Average Trading Volume: 334,567
Technical Sentiment Signal: Sell
Current Market Cap: HK$503.4M
See more insights into 1466 stock on TipRanks’ Stock Analysis page.